What Happened to Allergan’s Valuation after 2Q17?
Of the 21 analysts tracking Allergan stock, 14 recommend a “buy,” and seven analysts recommend a “hold.” None recommends a “sell.”
Allergan’s International segment reported a 13.4% YoY (year-over-year) rise in revenues to $858.5 million in 2Q17, compared with $757.0 million in 2Q16.
Allergan’s US General Medicines segment reported a 1.5% fall in revenues to $1.43 billion during 2Q17, compared to $1.45 billion in 2Q16.
Allergan’s US Specialized Therapeutics segment includes eye care, medical aesthetics, medical dermatology, and neuroscience and urology products.
Allergan’s US Specialized Therapeutics segment reported a ~15% rise in revenues to $1.7 billion in 2Q17, compared with $1.49 billion in 2Q16.
Allergan reported revenues of $4.01 billion for 2Q17—an 8.8% rise over 2Q16, driven by the strong performance of key brands in specialized therapeutics.
On September 19, 2017, Allergan’s Allure received three 2017 Best of the Beauty Breakthrough awards.
Amazon (AMZN) is reportedly in talks with some of the mid-market pharmacy benefit managers. It’s looking to pursue a mail-order pharmacy.
Analysts estimate that Pfizer (PFE) stock has the potential to return ~5.9% over the next 12 months.
Pfizer’s (PFE) Essential Health segment reported a fall in overall revenues in 2Q17, driven by the loss of exclusivity of Celebrex and Zyvox.
Pfizer’s (PFE) key products contributing to growth include Eliquis, Ibrance, Lyrica, Xalkori, Xeljanz, and Xtandi.
PFE reported revenues of nearly $12.9 billion for 2Q17, including nearly flat revenues at constant exchange, offset by the 2% negative impact of foreign exchange.
Pfizer’s Innovative Health segment contributed ~59% of PFE’s total revenues in 2Q17, and analysts expect the contribution to rise to ~60% in 3Q17.
Pfizer (PFE) reported revenues of ~$12.9 billion in 2Q17, which was ~2% lower than its revenues of ~$13.2 billion in 2Q16.
On September 14, Pfizer (PFE) and Astellas Pharma announced positive top-line results for their Prosper study, a phase-III study evaluating Xtandi with ADT.
On September 1, 2017, the FDA approved Pfizer’s drug Mylotarg (gemtuzumab ozogamicin) for the treatment of CD33-positive acute myeloid leukemia.
As we’ve discussed in this series, Walgreens received FTC (Federal Trade Commission) approval to acquire 1,932 Rite Aid store on September 19.
The stock price for Rite Aid (RAD) plunged more than 12% after the announcement of the deal closure with Walgreens on September 19.
On September 19, Walgreens Boots Alliance (WBA) finally received FTC (Federal Trade Commission) approval for its long-awaited transaction with Rite Aid Corporation (RAD).
Wall Street analysts have projected Zoetis’s 2017 net profit margins to be around 21.2%, which is year-over-year (or YoY) growth of around 440 basis points.